Reference : Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.
Scientific journals : Article
Human health sciences : Otolaryngology
http://hdl.handle.net/2268/101424
Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.
English
Gevaert, Philippe [> > > >]
Van Bruaene, Nicholas [> > > >]
Cattaert, Tom [Université de Liège - ULg > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique >]
Van Steen, Kristel mailto [Université de Liège - ULg > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique >]
Van Zele, Thibaut [> > > >]
Acke, Frederic [> > > >]
De Ruyck, Natalie [> > > >]
Blomme, Katrien [> > > >]
Sousa, Ana R [> > > >]
Marshall, Richard P [> > > >]
Bachert, Claus [> >]
2011
Journal of Allergy and Clinical Immunology (The)
Mosby
128
5
989-995.e8
Yes (verified by ORBi)
International
0091-6749
1097-6825
St Louis
MO
[en] BACKGROUND: Approximately 85% of nasal polyps (NPs) in white subjects are characterized by prominent eosinophilia. IL-5 is the key driver of eosinophilic differentiation and survival. OBJECTIVE: We sought to investigate the therapeutic potential of inhibiting IL-5 with a humanized mAb as treatment for severe nasal polyposis. METHODS: Thirty patients with severe nasal polyposis (grade 3 or 4 or recurrent after surgery) refractory to corticosteroid therapy were randomized in a double-blind fashion to receive either 2 single intravenous injections (28 days apart) of 750 mg of mepolizumab (n = 20) or placebo (n = 10). Change from baseline in NP score was assessed monthly until 1 month after the last dose (week 8). Computed tomographic scans were also performed at week 8. RESULTS: Twelve of 20 patients receiving mepolizumab had a significantly improved NP score and computed tomographic scan score compared with 1 of 10 patients receiving placebo at week 8 versus baseline. CONCLUSION: Mepolizumab achieved a statistically significant reduction in NP size for at least 1 month after dosing in 12 of 20 patients. IL-5 inhibition is a potential novel therapeutic approach in patients with severe eosinophilic nasal polyposis.
http://hdl.handle.net/2268/101424
10.1016/j.jaci.2011.07.056
Copyright A(c) 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Gevaert2011.pdfAuthor postprint757.28 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.